Compare iShares MSCI Taiwan ETF (EWT) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Taiwan ETF vs Gilead Sciences, Inc. — how do they compare? iShares MSCI Taiwan ETF trades at $100.25, while Gilead Sciences, Inc. trades at $136.36 (market cap $163.51B). The key difference: Gilead Sciences, Inc. pays a 2.49% dividend while iShares MSCI Taiwan ETF pays none, and iShares MSCI Taiwan ETF is trading nearer its 52-week high, Gilead Sciences, Inc. nearer its low. Which is the better fit depends on your goals.
| EWT | GILD | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $111.53 | $155.80 |
52-Week Low | $58.05 | $108.22 |
Market Cap | — | $163.51B |
Enterprise Value | — | $178.05B |
Dividend Yield | — | 2.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
The iShares MSCI Taiwan ETF (EWT) trades at $100.08, down 1.77% on the day, consolidating after a significant rally that saw the fund more than double over the past year. Technical indicators show a neutral overall signal with mixed moving average and oscillator readings, while the fund remains strategically positioned at the center of the global AI infrastructure surge through its heavy exposure to Taiwan's semiconductor sector, led by TSMC.
The outlook for EWT is balanced between strong fundamental tailwinds from AI-driven semiconductor demand and significant geopolitical risks related to Taiwan-China tensions. While the fund offers concentrated exposure to a critical technology supply chain, stretched valuations and potential currency headwinds create near-term uncertainty for investors.
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Taiwan ETF
EWT tracks the MSCI Taiwan 25/50 Index, providing targeted exposure to large and mid-cap companies in Taiwan. It is heavily concentrated in the information technology sector, serving as a liquid instrument for investors seeking a single-country view of Taiwan's export-oriented and tech-driven economy.
Read more on EWT →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
